

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the prospectus dated 31 January 2022 (the “**Prospectus**”) issued by Clarity Medical Group Holding Limited (the “**Company**”).*

*This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold outside of the United States as offshore transactions in accordance with Regulation S under the U.S. Securities Act.*

*Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.*



## **CLARITY MEDICAL GROUP HOLDING LIMITED**

## **清晰醫療集團控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1406)**

## **STABILISING ACTIONS, END OF STABILISATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION**

## **STABILISING ACTIONS AND END OF STABILISATION PERIOD**

The Company announces that the stabilisation period in connection with the Global Offering ended on Saturday, 12 March 2022, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of the stabilising actions undertaken by China Everbright Securities (HK) Limited through its affiliates, the Stabilising Manager, or any person acting for it, during the stabilisation period is set out in this announcement.

## **LAPSE OF THE OVER-ALLOTMENT OPTION**

The Joint Representatives (on behalf of the International Underwriters) did not exercise the Over-allotment Option during the stabilisation period, and the Over-allotment Option lapsed on Saturday, 12 March 2022.

## **STABILISING ACTIONS AND END OF STABILISATION PERIOD**

The Company announces that the stabilisation period in connection with the Global Offering ended on Saturday, 12 March 2022, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilising actions undertaken by China Everbright Securities (HK) Limited through its affiliates, the Stabilising Manager, or any person acting for it, during the stabilisation period are set out below:

- (i) over-allocations of an aggregate of 9,470,000 Offer Shares in the International Offering, representing 7.0% of the number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (ii) the borrowing of an aggregate of 9,470,000 Shares from Ultimate Bliss Limited pursuant to the Stock Borrowing Agreement to cover the over-allocations in the International Offering; and
- (iii) successive purchases of an aggregate of 9,470,000 Shares at the price range of HK\$1.44 to HK\$1.59 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and Financial Reporting Council transaction levy of 0.00015%) on the market during the stabilisation period, representing 7.0% of the number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option) to facilitate the return of 9,470,000 Shares borrowed from Ultimate Bliss Limited pursuant to the Stock Borrowing Agreement. The last purchase made by the Stabilising Manager, or any person acting for it, on the market during the stabilisation period was on 24

February 2022 at the price of HK\$1.47 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and Financial Reporting Council transaction levy of 0.00015%).

## **LAPSE OF THE OVER-ALLOTMENT OPTION**

The Joint Representatives (on behalf of the International Underwriters) did not exercise the Over-allotment Option during the stabilisation period, and the Over-allotment Option lapsed on Saturday, 12 March 2022.

## **PUBLIC FLOAT**

Immediately after the end of the stabilisation period, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules pursuant to which at least 25% of the Company's total number of issued Shares must at all times be held by the public.

By order of the Board  
**CLARITY MEDICAL GROUP HOLDING LIMITED**  
**WU Ting Yuk Anthony**  
*Non-Executive Director and Chairman*

Hong Kong, 13 March 2022

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. WONG Tai Cheung Andrew and Mr. LO Tsz Hong as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director, Mr. NG Roy and Ms. ZHAO Wei as non-executive Directors and Mr. LI Michael Hankin, Mr. HUI Yung Chris and Mr. MA Wai Hung Vincent as independent non-executive Directors.*